Following program cuts and amid drug launch, Roivant lines up $1B shelf registration
Roivant Sciences had about $2 billion at the end of June. But the repeat vant-maker wants the option to secure more money for its apparatus, according to paperwork with the SEC.
A shelf registration statement with multiple prospectuses, including a sales agreement via the help of Cowen, was filed with the agency on Monday. Roivant is offering up a total of $1 billion.
Roivant currently has no plans to use the potential proceeds, a spokesperson tells Endpoints News via email. “We did it now because under securities law we weren’t allowed to have a shelf until this month because of when we went public,” the spokesperson wrote. Roivant landed on the Nasdaq last year in a highly watched SPAC merger that gave the combined company a $7.3 billion valuation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.